Staphylococcus aureus is a major pathogen both within hospitals and in the community. Methicillin, a ␤-lactam antibiotic, acts by inhibiting penicillinbinding proteins (PBPs) that are involved in the synthesis of peptidoglycan, an essential mesh-like polymer that surrounds the cell. S. aureus can become resistant to methicillin and other ␤-lactam antibiotics through the expression of a foreign PBP, PBP2a, that is resistant to the action of methicillin but which can perform the functions of the host PBPs. Methicillinresistant S. aureus isolates are often resistant to other classes of antibiotics (through different mechanisms) making treatment options limited, and this has led to the search for new compounds active against these strains. An understanding of the mechanism of methicillin resistance has led to the discovery of accessory factors that influence the level and nature of methicllin resistance. Accessory factors, such as Fem factors, provide possible new targets, while compounds that modulate methicillin resistance such as epicatechin gallate, derived from green tea, and corilagin, provide possible lead compounds for development of inhibitors. Pharmacy, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . His research interests include the mechanisms of antibiotic resistance, antibiotic resistance gene capture and spread, and the development and mode of action of new antimicrobial agents.
Introduction
vancomycin resistance conferring genes from other bacterial groups can be expressed in S. aureus and with the emergence of glycopeptide-intermediate resistant S. aureus strains 2 the search for new antistaphylococcal agents is a pressing issue. One approach to combat resistance is to find novel targets, while another is to find agents that can reduce or moderate resistance to an existing antibiotic. Investigations into methicillin resistance in S. aureus has led to the discovery of new proteins involved in cell wall synthesis that might act as targets and compounds that modulate methicillin resistance. This review focuses on both the mechanisms and the factors that modulate methicillin resistance in S. aureus.
Penicillin-binding proteins: the targets of ␤-lactam antibiotics
The staphylococcal cell is surrounded by a mesh-like structure 20-40 nm thick, called peptidoglycan, that is composed of a series of short glycan chains of approximately 20 alternating N-acetyl-Methicillin resistance in Staphylococcus aureus 59 muramic acid and ␤-1-4-N-acetylglucosamine residues 3 . Attached to each N-acetylmuramic acid residue is a pentapeptide chain referred to as the stem peptide. The glycan chains in peptidoglycan are linked together via the last glycine residue of a pentaglycine cross-bridge attached to the L-lys residue (position 3) on one stem peptide and the D-Ala residue (position 4) on another ( Figure 2) . Pentaglycine crossbridges are preformed in the cytoplasm by the FemX, FemA, and FemB proteins, which attach the glycine residues to the L-lysine residue of the stem peptides 4 . The cross-linking or transpeptidation reactions take place on the external surface of the cytoplasmic membrane in a reaction catalysed by penicillin-binding proteins (PBPs). There are four PBPs in S. aureus, PBP1, PBP2, PBP3, and PBP4. High molecular weight PBPs have two protein domains, one involved in transpeptidation (cross-linking) the other involved in transglycosylation (extending the glycan chain). The ␤-lactam antibiotics, which resemble the terminal D-alanyl-D-alanine bond of the stem peptide, inhibit the transpeptidation domain of PBPs (and carboxypeptidase activity of low molecular weight PBPs) thus interfering with the cross-linking reaction. Without cross-linking of the peptidoglycan, the cell wall becomes mechanically weak, some of the cytoplasmic contents are released and the cell dies 3 .
Methicillin resistance
Methicillin resistance in clinical isolates has been reported to arise from expression of a methicillin-hydrolysing ␤-lactamase 5 through the expression of an altered form of PBP2 that has a lower penicillin-binding affinity and higher rates of release of the bound drug compared to the normal PBP2 6 . However, the main mechanism of methicillin resistance in S. aureus is through the expression of a foreign PBP, PBP2a (not to be confused with PBP2), that is resistant to the action of methicillin but which can takeover the transpeptidation (cross-linking) reactions of the host PBPs. Synthesis of PBP2a is regulated and normally kept at low level, but the level of synthesis can be enhanced if mutations occur in the regulatory genes. PBP2a and the control of PBP2a synthesis are described below.
PBP2a
MRSA differ genetically from methicillin-sensitive S. aureus isolates by the presence, in the chromosome, of a large stretch of foreign DNA (40-60 Kb), referred to as the mec element, and the presence of the mecA gene that encodes the 76 KDa penicillin-binding protein, PBP2a (also referred to as PBP2′). The mecA gene has been proposed to originate from Staphylococcus sciuri 7 . Although the mechanism of gene acquisition from this specie is not known, two genes, ccrA and ccrB, present on the mec element from one isolate, have been shown to code for recombinase proteins that are capable of excising and integrating the mec element into the chromosome 8 . Examination of a large number of MRSA isolates has led to the conclusion that the original acquisition of the mecA gene has occurred once and that MRSA isolates are descendants of a single clone 9 . Although the arrangement and composition of the mec element may vary between isolates 10 , the mecA gene itself is highly conserved. In common with other PBPs, PBP2a has the common structural motifs that are associated with penicillin binding yet its affinity for ␤-lactam antibiotics is greatly reduced. Consequently, at therapeutic levels of methicillin that would inhibit the transpeptidational activities of other PBPs, PBP2a remains active ensuring the cross-linking of the glycan chains in peptidoglycan. PBP2a is not able to completely compensate for the other PBPs since cells grown in the presence of methicillin exhibit a marked reduction in the degree of cross-linking. However, the limited degree of cross-linking is enough to ensure survival of the cell.
Regulation of PBP2a expression
Adjacent to mecA on the staphylococcal chromosome are two genes, mecR1 and mecI, that are co-transcribed divergently from mecA ( Figure 3A ). The mecR1 gene encodes a membrane-bound signal transduction protein (MecR1) while mecI encodes a transcriptional regulator (MecI). Between mecA and mecR1 are the promoters for these genes and an operator region that encompasses the -10 sequence of mecA and the -35 sequence of mecR1 ( Figure 3A) 11 . MecR1 and MecI have high protein sequence homology with the proteins, BlaR1 and BlaI, respectively, that are involved in the inducible expression of the plasmid-mediated staphylococcal ␤-lactamase gene, blaZ. The arrangement of the genes coding for BlaR1 and BlaI resembles the mecA system suggesting that mecA may have acquired the regulatory genes from the blaZ system sometime in the past 12 . The operator regions are similar enough to allow BlaI to regulate PBP2a expression 13 . Consequently, the presence of a plasmid carrying the blaZ regulatory genes can render PBP2a expression inducible under the control of BlaR1 and BlaI, a situation that commonly occurs in clinical isolates of MRSA 14 .
The nature of the signalling system for inducible ␤-lactamase expression has recently been elucidated 15 . BlaI, a DNA-binding protein, binds to the operator region as a homodimer and represses RNA transcription from both blaZ and blaR1-blaI ( Figure 3B ). Consequently, in the absence of a ␤-lactam antibiotic, ␤-lactamase is expressed at low levels. BlaR1, present in the cytoplasmic membrane, detects the presence of the ␤-lactam by means of an extracellular penicillin-binding domain and transmits the signal via a second intracellular zinc metalloprotease signalling domain ( Figure 3B ). Binding of a ␤-lactam to BlaR1 stimulates the autocatalytic conversion of the intracellular zinc metalloprotease domain of BlaR1 from an inactive proenzyme to an active protease 15 . The activated form of BlaR1 is thought to directly or indirectly cleave BlaI resulting in fragments that are incapable of forming dimers and binding DNA ( Figure 3C ) 13 . Without BlaI bound to the operator site, transcription of both blaZ and blaR1-blaI can commence and ␤-lactam resistance can be conferred through ␤-lactamase synthesis ( Figure 3C ). An additional gene product, BlaR2, also regulates ␤-lactamase synthesis, although the role of this protein has not been elucidated. Whether there are other proteins involved in the signalling system also remains to be determined.
Unlike ␤-lactamase synthesis, expression of PBP2a is not strongly inducible in isolates carrying the normal regulatory genes (mecA and mecR1-mecI) and induction is much slower (15 minutes for ␤-lactamase expression compared to up to 48 hours for PBP2a synthesis). This is because MecI is a tight regulator of mecA transcription 16 and most ␤-lactam antibiotics do not efficiently activate MecR1. Consequently, some isolates, referred to as pre-MRSA, are methicillin-sensitive despite carrying the mecA gene. However, selective pressure though antibiotic usage has promoted S. aureus isolates that have mutations or deletions in mecI or the mecA promoter/ operator region giving rise to an inactive repressor and constitutive PBP2a expression 17 . Isolates carrying these mutations can have one of two methicillin resistance phenotypes, homogeneous or heterogeneous, depending on the population structure of a given strain. Homogeneous resistance refers to a cell population where all cells are resistant to high concentrations of methicillin (> 128 mg/l), while heterogeneous resistance refers to a cell population where only a small minority of cells exhibit high-level methicillin resistance. The small minority of cells that exhibit high-level resistance in the heterogeneous population are due to an additional chromosomal mutation(s), designated chr*, that occurs outside of the mec element 18 . The nature of the chr* mutations that give rise to homogeneous methicillin resistance are not known but mutations in the newly described hmr loci may be responsible in some cases 19 .
Modulation of methicillin resistance
PBP2a synthesis is regulated by MecI and MecR1 proteins and, when present, the regulatory/ signalling proteins of the blaZ system. In addition, homogeneous resistance is dependent upon mutations at a separate genetic locus, chr*. Other factors both internal and external also influence methicillin resistance.
Internal factors affecting methicillin resistance
Since PBP2a is essential in conferring methicillin resistance, any factor that interferes with the expression of the mecA gene or with the activity of PBP2a will affect methicillin resistance. Genetic and biochemical studies have established that PBP2a has strict substrate requirements. Consequently, any factors that influence formation of the substrate have the potential to perturb or modulate methicillin resistance. In this context, early inhibitors of cell wall synthesis such as fosfomycin, ␤-chloro-D-alanine, and D-cycloserine have been shown to reduce methicillin resistance 20 . Studies have shown that PBP2a requires:
(i) Glycan chains to be of certain lengths. PBP2a is dependent upon the transglycosylase activity of PBP2. ␤-lactams inhibit the transpeptidase domain of high molecular weight PBPs but do not affect the transglycosylase domain. Inactivation of the transglycosylase domain of PBP2, results in an increase in glycan chains of shorter lengths and a marked decrease in methicillin resistance 21 . Therefore, compounds that target the transglycosylase domains of PBPs could serve as useful therapeutic agents. (ii) The stem peptide to have the normal peptide configuration. The addition of glycine to the growth medium leads to stem peptides of peptidoglycan ending in two glycine residues instead of two alanine residues. This leads to a decrease in methicillin resistance and conversion of a highly resistant homogeneous strain to a heterogeneous phenotype 22 . Inactivation of murE (femF), the gene coding for UDP-N-acetylmuramyl tripeptide synthetase, also gives rise to a reduction in methicillin resistance.
(ii) This results from a reduction of UDP-linked muramyl pentapeptides and accumulation of UDP-linked muramyl dipeptides in the cell wall precursor pool 23 . These results illustrate that PBP2a requires the stem peptides to have the correct length and contain the normal series of peptides. (iii) Requires the pentaglycine cross-bridge to be intact. FemA, FemB and FemX (FmhB) are involved in building the pentaglycine cross-bridges that link the glycan chains together 4 . FemX adds the first glycine, FemA adds glycines 2 and 3, and FemB adds glycines 4 and 5. FemA and FemB are not interchangeable, consequently inactivation of the genes coding for either of these proteins results in cell walls that contain monoor triglycine cross-bridges, respectively. Inactivation of either of the femA or femB genes is thought to be lethal but compensatory mutations can restore cell viability, although growth is severely affected 4 . Significantly, inactivation of either femA or femB also results in a large reduction in methicillin resistance. Consequently, the FemA and FemB proteins represent new targets for drug development 24 . Inactivation of FemA and FemB has the added advantage in that interference with the cross-bridge length also affects the secretion of virulence factors which could limit the ability of the cell to cause infection 25 . Incidentally, the Lif protein that adds serine residues in the cross-bridges of other staphylococcal species, complements the activity of FemB by incorporating serine residues at positions 4 and 5 26 . Introduction of serine residues into the cross-bridge results in a reduction in methicillin resistance indicating that PBP2a can only handle cross-bridges containing glycine at positions 4 and 5 26 . So it is possible that the development of inhibitors of FemA and FemB, might not be compromised by the acquisition of other cross-bridge building proteins from other species.
Peptidoglycan synthesis requires the coordinated activity of not only the biosynthetic enzymes but also the lytic enzymes that are involved in peptidoglycan remodelling and cell division. Methicillin resistance is affected by the inactivation of genes that affect the autolytic enzyme activities of the cell. Inactivation of the llm gene, coding for a protein of unknown function, converts a homogeneous strain to a heterogeneous phenotype and is associated with increased autolytic activity 27 . The activities of the global regulator proteins such as Sar, Agr and SigmaB are also known to affect methicillin resistance 4 . Their affects are probably mediated through their control of genes involved in cell wall and exoprotein synthesis.
External factors that affect methicillin resistance
External factors that affect methicillin resistance include among others, salt concentration, pH, medium composition, osmolarity and temperature 28 . Some of these external influences are exploited in the clinical laboratory to enhance the detection of strains exhibiting heterogeneous methicillin resistance; isolates are grown in the presence of high NaCl concentrations (2%) and at lower temperatures (30-35°C) . Why NaCl concentration and temperature have this affect is not known.
Compounds that modulate methicillin resistance
Baicalin, a flavone compound isolated from the Chinese herb Xi-nan Huangqin (Scutellaria amoena) 29 and a tripeptide, LY301621 (carbobenzoxydiphenylalanine-proline-phenylalanine alcohol) 30 , increase the susceptibility of MRSA isolates to ␤-lactams but the mechanism of how they achieve this is not understood. A few compounds are known to affect the expression of the mecA gene. For compounds such as the polyoxotungstates 31 and totarol 32 , the synthesis of PBP2a is reduced but the mechanism of how this is achieved is not known. For others, such as polidocanol (a dodecyl polyethyleneoxide ether) 33 , and glycerol monolaurate 34 the site of action is thought to be the cytoplasmic membrane where they interfere with either the signalling domain of MecR1 or some other protein involved in signal transduction. The non-ionic detergent Triton X-100 is also thought to target the cytoplasmic membrane but it does not interfere with PBP2a production. Strains grown in the presence of Triton X-100 have increased susceptibility to methicillin and have increased rates of bacteriolysis 35 . MRSA grown in the presence of triton X-100 are converted from a homogeneous to a heterogeneous phenotype, although there appears to be strain-to-strain variability. Inactivation (or partial disruption) of the fmt genes, fmtA and fmtB, have been shown to enhance triton X-100mediated methicillin sensitivity. The FmtA protein is a membrane protein that has two of three conserved ␤-lactam binding motifs but it does not bind ␤-lactams 36 . Inactivation of the fmtA gene affects the cell wall structure but the precise role of the FmtA protein has not been determined. How the inactivation of the fmtB gene results in a reduction in methicillin resistance is also not known, but methicillin resistance can be restored by the addition of cell wall precursors, glycosamine-1-phosphate and N-acetylglycosamine-1-phosphate 37 .
Other compounds are known not to affect PBP2a synthesis and interfere with the activity of PBP2a, these include licoricidin, a phenolic compound isolated from commercial licorice 38 , and the triazine dye, cibacron blue F3GA 39 .
Epicatechin gallate (ECG) and epigallocatechin gallate (EGCG) (Figure 4 ) are polyphenolic compounds present in green tea (Camellia sinensis) that have activities against a wide range of bacteria 40 . At high concentrations epicatechin gallate selectively inhibits the growth of methicillin-resistant S. aureus. Under the electron microscope cells treated with green tea extracts have gross morphological changes characterised by the clumping together of partial divided cells that have thickened internal cell walls 41 . Methicillin-sensitive strains appear to be unaffected by the extract. At low concentrations (25 mg/l), both ECG and EGCG can modulate methicillin resistance and act synergistically with ␤-lactams such as methicillin and oxacillin 42 . The action of ECG in combination with oxacillin is bactericidal 43 . EGCG does not appear to affect transcription of the mecA gene and has been proposed to exerts its effect through direct binding to peptidoglycan 44 . However, other workers have shown that an extract of green tea (ECG) affects the quantities of PBP1, PBP3 and PBP2a but not PBP2, present in the cytoplasmic membrane, suggesting a more specific mode of action 42 . The effect on PBP3 expression might be significant since, cephradine (a type of ␤-lactam antibiotic) a relatively selective inhibitor of PBP3 has an inhibitory affect on methicillin resistance at sub-minimum inhibitory concentrations suggesting a role for PBP3 in methicillin resistance 20 . ECG and EGCG have also been shown to damage bacterial membranes 45 .
Green tea administered as a spray has been successfully used in the treatment of an MRSA infection of the trachea (windpipe) 46 . Unfortunately, epicatechin gallate cannot by widely administered because it is broken down by esterases in the body to the inactive products, epicatechin and gallic acid. This prevents the oral or parenteral co-administration of ECG with oxacillin or methicillin. Recently, two other polyphenolic compounds, corilagin 47 , extracted from the leaves of Arctostaphylos uva-ursi and tellimagrandin I 48 extracted from the petals of rose red (Rosa canina L.) have been reported. Both compounds act synergistically with oxacillin. Corilagin appears to interfere with PBP2a activity rather than PBP2a synthesis and has greater activity against MRSA than either ECG or tellimagrandin I 47 . Further investigations into the mechanisms of action of these polyphenolic compounds combined with the synthesis of more stable derivatives are warranted.
Concluding remarks
Peptidoglycan synthesis is a complex process involving the coordination of both biosynthetic and degradative pathways. PBP2a is not native to S. aureus, and has to fit within this system. Unfortunately, PBP2a is less sensitive to the action of methicillin and is capable of conferring methicillin resistance. Fortunately, the substrate requirements of PBP2a are relatively strict and this is a weakness that can be exploited. By targeting and inhibiting the proteins, such as FemA and FemB, involved the formation of these substrates, methicillin resistance can be modulated. Compounds such as epicatechin gallate and corilagin are attractive compounds to develop into therapeutic agents since these compounds exist already and are known to modulate methicillin resistance.
